06/16/2025 | Press release | Distributed by Public on 06/16/2025 05:00
As previously disclosed on June 1, 2025, Ms. Fangqin Lin notified the Company of her resignation as an independent director, effective June 1, 2025.
On June 12, 2025, approved by the Board of Directors, the Nominating Committee and the Compensation Committee, Mr. Heng Wee Koon was appointed as independent director and chair of compensation committee of the Company, effective June 12, 2025.
The biographical information of Mr. Heng Wee Koon is set forth below:
Mr. Heng Wee Koon has over two decades of experience in mergers and acquisitions advisory, financial due diligence, and strategic consulting. Mr. Heng began his career at KPMG, where he served from October 2008 to December 2016, including as a Partner at KPMG Advisory LLP. There, he led deal advisory engagements across various sectors, specializing in M&A due diligence and related support services. In 2017, he transitioned to the corporate sector as Chief Operating Officer at Biomax Green Pte. Ltd., focusing on strategic collaborations and cross-border operations. Since then, he has held leadership roles at several consulting and advisory firms, including as Director of E.R.S. Advisory Pte Ltd, Senior Advisor at Nihon M&A Center Singapore, and currently as Executive Director and founder of Acelyr M&A Pte Ltd and Acelyr Advisory Pte Ltd. Mr. Heng also serves as Lead Independent Director of Hyphens Pharma International Limited, where he chairs the Audit Committee. He holds a Bachelor of Business Administration with Honours from the National University of Singapore and a Master of Business Administration from Nanjing University.
Mr. Heng Wee Koon entered into an independent director offer letter with the Company and agreed to receive an annual compensation of $30,000, effective June 12, 2025.
1
EXHIBIT INDEX
Exhibit No. | Description | |
10.1 | Independent Director Offer Letter to Mr. Heng Wee Koon, dated June 12, 2025 |
3